MedTrace Logo

Use of Sildenafil Citrate in Management of Mild Pre-eclampsia

NCT03262961 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2017-08-28

No results posted yet for this study

Summary

* Mild pre-eclampsia represents 75% of cases with pre-eclampsia, possible progression to severe pre-eclampsia makes mild pre-eclampsia a serious problem that requires attention.
* Previous studies have shown that expectant and conservative management of pre-eclampsia in the context of extreme prematurity may improve perinatal outcomes. Indeed, it has been estimated that for each additional day of pregnancy prolongation between 24 and 32 weeks of gestation, there is a nonlinear corresponding gain of 1% in fetal survival.
* Sildenafil citrate has been used for increasing utero-placental perfusion in cases with intrauterine growth restriction, which makes it a promising drug in management of mild pre-eclampsia.

Conditions

  • Pre-Eclampsia; Mild

Interventions

DRUG

Sildenafil 20 MG

DRUG

Placebo Oral Tablet

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Fady Abdallah · Assiut University

  • Hasan Kamel · Assiut University

  • Hisham Abou-Taleb · Assiut University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-15
Primary Completion
2017-12-15
Completion
2018-01-15

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03262961 on ClinicalTrials.gov